Licensing, distribution or full market access — choosing the model

Partners usually arrive having already decided the structure — “we’re looking for a distributor” — and the structure is often wrong for what they actually need. Four models cover almost every European entry. They differ in one dimension that matters more than the commercial terms: who holds the regulatory role, and who carries the stock.

1. Distribution agreement

You retain the product, the registration and the brand. A local partner buys and resells into their channel.

Demands of you: regulatory responsibility stays yours, including claim compliance in a market whose enforcement culture you may not know. You supply master data, artwork and pharmacy-facing material, and you carry the consequences if the partner’s marketing steps outside the framework.

When it fits: you have a settled classification, defensible claims and a product that does not need local adaptation. Cheapest to start.

Where it fails: a distributor with no exclusivity and a broad catalogue has little reason to prioritise your line. Rotation stalls, and you find out two quarters later.

2. In-licensing to a local operator

You license the product to a party who takes it into their own portfolio for a defined territory and channel. They take the operating role; you take a royalty or transfer price.

Demands of you: clean documentation. A licensee inherits your regulatory position, so anything unresolved becomes a negotiation point and then a liability allocation.

When it fits: you want the market without building an operating structure in it, and you would rather have a smaller share of a run business than a larger share of a stalled one.

Where it fails: if the asset’s regulatory route is genuinely unresolved, no serious licensee will take it at a price you like — and the ones who will are the ones you should not sign.

3. Full market access under an operating partner

A partner carries the whole path: regulatory route, quality documentation, listing, commercialisation, and often the marketing authorisation role where one applies.

Demands of you: the least operationally, the most in due diligence. You are selecting an organisation, not negotiating a contract, and their documented responsibilities, quality system and channel relationships are the substance of the deal.

When it fits: entering a category or region where you have no infrastructure and where the regulatory route is non-trivial — which describes most non-EU brands entering DACH.

Where it fails: if you need day-to-day control of positioning. You are buying an operator’s judgement; overriding it repeatedly removes the reason to have engaged one.

4. Out-licensing your own asset

The mirror image: you hold rights you cannot commercialise locally and license them out.

Demands of you: an orderly transition — documentation, registration, stock — without a gap in supply. This is where most out-licensing deals actually go wrong, long after the terms are agreed.

When it fits: a product line that is sound but not strategic, or a territory you will never serve directly.

The question that decides it

Not “what does it cost” but “who is accountable when a batch is queried on a Friday afternoon?” Work backwards from the answer:

• If the answer must be you, take distribution and accept the control burden.
• If the answer can be someone else, and the regulatory route is settled, in-license.
• If the answer must be someone else and the route is not settled, full market access is the only structure that does not leave the hardest problem unowned.

What every model needs regardless

A quality annex allocating responsibilities explicitly between the parties, aligned to the GMP/GDP scope; defined territory and channel; minimums; duration; and exit provisions written while everyone is still cooperative.

The commercial terms determine whether the deal is good. The quality annex determines whether it survives.

---

We sit on both sides of this table — as licensor of our own brands and as licensee for partner products. See licensing & partnerships.